Did you miss last night's "Mad Money" on CNBC? If so, here are some of Jim Cramer's top takeaways.

For his "Executive Decision" segment, Cramer spoke with Mick Farrell, CEO of ResMed (RMD) , the medical device maker combating sleep apnea. The company just delivered a three-cents-a-share earnings beat on a 16.7% rise in revenues.

Farrell said that RedMed now has more than two million cloud-connected devices in use but still only has 20% penetration of its core market. The company is also expanding its market to address chronic obstructive pulmonary disease, or COPD, where ResMed currently has less than 1% market share.

The medical community is beginning to recognize the value in keeping patients happy and healthy in their homes and out of hospitals and urgent care, Farrell said.

ResMed is also making powerful partnerships, such as with celebrity physician Dr. Mehmet Oz, who is a big advocate of sleep wellness.

Cramer is advising his investment club members to hold steady in the middle of all this market and political uncertainty. Get a free subscription to Action Alerts PLUS.

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

To read a full recap of this episode of "Mad Money," click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had no position in stocks mentioned.

If you liked this article you might like

Here's Why This Rally Is Sustainable: Cramer's 'Mad Money' Recap (Tuesday 1/24/17)

Why CarMax and Garmin Could Be Prime Candidates for a Short Squeeze

Why a Massive Short Squeeze Could Send These 4 Stocks Into Orbit

ResMed (RMD) Stock Sharply Lower After Q1 Results Miss Estimates